Yang Yang, Jin Xin, Jiao Xinyi, Li Jinjing, Liang Liuyi, Ma Yuanyuan, Liu Rui, Li Zheng
State Key Laboratory of Component-Based Chinese Medicine, College of Pharmaceutical Engineering of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Military Medicine Section, Logistics University of Chinese People's Armed Police Force, Tianjin 300309, China.
Evid Based Complement Alternat Med. 2020 Dec 31;2020:8871105. doi: 10.1155/2020/8871105. eCollection 2020.
Chronic obstructive pulmonary disease (COPD) is a common respiratory disease with high morbidity and mortality. The conventional therapies remain palliative and have various undesired effects. Flavonoids from traditional Chinese medicine (TCM) have been proved to exert protective effects on COPD. This review aims to illuminate the poly-pharmacological properties of flavonoids in treating COPD based on laboratory evidences and clinical data and points out possible molecular mechanisms. Animal/laboratory studies and randomised clinical trials about administration of flavonoids from TCM for treating COPD from January 2010 to October 2020 were identified and collected, with the following terms: chronic obstructive pulmonary disease or chronic respiratory disease or inflammatory lung disease, and flavonoid or nature product or traditional Chinese medicine. Pharmacokinetic studies and external application treatment were excluded. A total of 15 flavonoid compounds were listed. Flavonoids could inhibit inflammation, oxidative stress, and cellular senescence, restore corticosteroid sensitivity, improve pulmonary histology, and boost pulmonary function through regulating multiple targets and signaling pathways, which manifest that flavonoids are a group of promising natural products for COPD. Nevertheless, most studies remain in the research phase of animal testing, and further clinical applications should be carried out.
慢性阻塞性肺疾病（COPD）是一种常见的呼吸系统疾病，发病率和死亡率都很高。传统疗法仍然只能缓解症状，且有各种不良影响。中药中的黄酮类化合物已被证明对COPD有保护作用。本综述旨在基于实验室证据和临床数据阐明黄酮类化合物在治疗COPD中的多药特性，并指出可能的分子机制。检索并收集了2010年1月至2020年10月期间关于使用中药黄酮类化合物治疗COPD的动物/实验室研究和随机临床试验，检索词如下：慢性阻塞性肺疾病或慢性呼吸系统疾病或炎症性肺病，以及黄酮类化合物或天然产物或中药。排除了药代动力学研究和外用治疗。共列出了15种黄酮类化合物。黄酮类化合物可以通过调节多个靶点和信号通路来抑制炎症、氧化应激和细胞衰老，恢复皮质类固醇敏感性，改善肺组织学，并提高肺功能，这表明黄酮类化合物是一组有前景的用于治疗COPD的天然产物。然而，大多数研究仍处于动物试验的研究阶段，应进一步开展临床应用。
